PT  - JOURNAL ARTICLE
AU  - Eyheramendy, Susana
AU  - Saa, Pedro A.
AU  - Undurraga, Eduardo A.
AU  - Valencia, Carlos
AU  - López, Carolina
AU  - Méndez, Luis
AU  - Pizarro-Berdichevsky, Javier
AU  - Finkelstein-Kulka, Andrés
AU  - Solari, Sandra
AU  - Salas, Nicolás
AU  - Bahamondes, Pedro
AU  - Ugarte, Martín
AU  - Barceló, Pablo
AU  - Arenas, Marcelo
AU  - Agosin, Eduardo
TI  - Improved screening of COVID-19 cases through a Bayesian network symptoms model and psychophysical olfactory test
AID  - 10.1101/2021.01.18.21249821
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.18.21249821
4099  - http://medrxiv.org/content/early/2021/01/20/2021.01.18.21249821.short
4100  - http://medrxiv.org/content/early/2021/01/20/2021.01.18.21249821.full
AB  - The infectiousness and presymptomatic transmission of COVID-19 hinder pandemic control efforts worldwide. Therefore, the frequency of testing, accessibility, and immediate results are critical for reopening societies until an effective vaccine becomes available for a substantial proportion of the population. The loss of sense of smell is among the earliest, most discriminant, and prevalent symptoms of COVID-19, with 75-98% prevalence when clinical olfactory tests are used. Frequent screening for olfactory dysfunction could substantially reduce viral spread. However, olfactory dysfunction is generally self-reported and not measured, which is specially problematic as partial olfactory impairment is broadly unrecognized. To address this limitation, we developed a rapid psychophysical olfactory test (KOR) deployed on a web platform for automated reporting and traceability based on a low-cost, six-odor olfactory identification kit. Based on test results, we defined an anosmia score –a classifier for olfactory impairment–, and a Bayesian Network (BN) model that incorporates other symptoms for detecting COVID-19 cases. We trained and validated the BN model on two samples: suspected COVID-19 cases in five healthcare centers (n = 926; 32% COVID-19 prevalence) and healthy (asymptomatic) mining workers (n = 1, 365; 1.1% COVID-19 prevalence). All participants had COVID-19 assessment by RT-PCR assay. Using the BN model, we predicted COVID-19 status with 76% accuracy (AUC=0.79 [0.75 − 0.82]) in the healthcare sample and 84% accuracy (AUC=0.71 [0.63 − 0.79]) among miners. The KOR test and BN model enabled the detection of COVID-19 cases that otherwise appeared asymptomatic. Our results confirmed that olfactory dysfunction is the most discriminant symptom to predict COVID-19 status when based on olfactory function measurements. Overall, this work highlights the potential for low-cost, frequent, accessible, routine testing for COVID-19 surveillance to aid society’s reopening.Competing Interest StatementDICTUC SA. has interest in commercial application of the olfactory test. E.A. is an advisor for DICTUC SA. C.V. and C.L. are employed by DICTUC SA.Clinical TrialThis prospective study was not performed under a clinical setting and thus it was not registered in internationally recognized trial registries.Funding StatementThis work was funded by the Technological Adoption Fund SiEmpre from SOFOFA Hub (CORFO), and partially funded by ANID through the Millennium Science Initiative Program ICN17_002 to S.E., P.B. and M.A.; ANID Millennium Science Initiative Program NCN17_081 and ANID/FONDAP CIGIDEN 15110017 to EU; and Fondecyt 1200146 to S.E.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Pontificia Universidad Catolica de Chile, who is the academic entity overseeing clinical studies in the UC-Christus health care centers, has approved the execution of this study. The conditions under which this study was approved are the following: 1. Patient personal data is private and will not be disclosed. 2. Patient clinical data must be anonymized for the study. 2. Patients are all informed about the features and application protocol of the olfactory test. All patients must sign the appropriate consent for a non-invasive medical test upon application.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes